Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Magrolimab (Hu5F9-G4) Phase 1 in Advanced Solid Tumors
NCT02216409Phase 1Completed
- Sponsor
- Gilead Sciences
- Start
- Aug 2014
- Primary completion
- Oct 2018
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of magrolimab in solid tumor and lymphoma, sponsored by Gilead Sciences. Primary endpoint: Safety and Tolerability of Hu5F9-G4 at 28 days. Started Aug 2014; status: completed.
02
Drugs
magrolimab
03
Conditions
solid tumorlymphoma
Beyond the preview
Go deeper on NCT02216409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02216409.